H7N1 Pandemic Influenza Vaccine (Adults)

A phase I/II single-blind, randomized, controlled, multi-center trial to evaluate the safety and immunogenicity of different formulations of monovalent Influenza A/mallard/Netherlands/12/2000 NIBRG-63 (H7N1) vaccine manufactured in Quebec, Canada with and without AS03 adjuvant, given as a two-dose series to adults 21 to 64 years of age.

Register Today!

Trial Information

Trial Duration12 months
Number of Visits7
Lead CRCJessica Richer

For additional information
on this trial contact: